Comparative Pharmacology
Head-to-head clinical analysis: HEPZATO versus THIOTEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPZATO versus THIOTEPA.
HEPZATO vs THIOTEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
None Documented
None Documented
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Deslanoside
"Thiotepa may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThiotepa + Acetyldigitoxin
"Thiotepa may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent